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Abstract
Background: Ionizing radiation (IR) exposure often occurs for human beings through occupational, medical, environmental,
accidental and/or other sources. Thus, the role of radioprotector is essential to overcome the complex series of overlapping
responses to radiation induced DNA damage.
Methods and Results: Treatment of human glioma U87 cells with DMA (5- {4-methylpiperazin-1-yl}-2-[29-(3, 4-
dimethoxyphenyl)-59-benzimidazolyl] in the presence or absence of radiation uncovered differential regulation of an array
of genes and proteins using microarray and 2D PAGE techniques. Pathway construction followed by relative quantitation of
gene expression of the identified proteins and their interacting partners led to the identification of MAP3K14 (NFkB
inducing kinase, NIK) as the candidate gene affected in response to DMA. Subsequently, over expression and knock down of
NIK suggested that DMA affects NFkB inducing kinase mediated phosphorylation of IKKa and IKKb both alone and in the
presence of ionizing radiation (IR). The TNF-a induced NFkB dependent luciferase reporter assay demonstrated 1.65, 2.26
and 3.62 fold increase in NFkB activation at 10, 25 and 50 mM DMA concentrations respectively, compared to control cells.
This activation was further increased by 5.8 fold in drug + radiation (50 mM +8.5 Gy) treated cells in comparison to control.
We observed 51% radioprotection in control siRNA transfected cells that attenuated to 15% in siRNA NIK treated U87 cells,
irradiated in presence of DMA at 24 h.
Conclusions: Our studies show that NIK/IKK mediated NFkB activation is more intensified in cells over expressing NIK and
treated with DMA, alone or in combination with ionizing radiation, indicating that DMA promotes NIK mediated NFkB
signaling. This subsequently leads to the radioprotective effect exhibited by DMA.
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Introduction
Exposure to IR, as well as other stresses, triggers several
complex signaling pathways, including DNA damage recognition
and repair, induction of cell cycle checkpoints, senescence and/
or apoptosis [1,2]. Damage to other cellular components, such as
the cell membrane, mitochondria, endoplasmic reticulum, and
non-DNA constituents of chromatin, may also initiate or modify
stress signaling in response to IR. Some of the important
pathways responding to radiation include the ATM/P53path-
way, MAPK cascades and NFkB activation, as well as signaling
events initiated at the cell membrane and within the cytoplasm
[3]. The signalling loop concept exists as activation of membrane
and cytoplasmic kinases in response to DNA damage inflicted by
ionizing radiation. A complex of nuclear factor-kB (NFkB),
essential modulator and ataxia telangiectasia- mutated kinase
activated by genotoxic agents is sent to cytoplasm, prompting
nuclear translocation of the active transcription factor NFkB. In
parallel, linear signalling pathways are initiated in the cytoplasm,
mostly by reactive oxygen species (ROS), resulting in NFkB
activation and nuclear translocation. The choice of NFkB
activation pathway and the extent of activation of various
pathways may be influenced by the relative degree of damage
inflicted by genotoxic agents in the nuclear and cytoplasmic
compartments. The ultimate pattern of cellular response is
determined by availability, abundance and localization of the
proteins participating in the signal transduction. The fate of
damaged cells depends on the balance between pro- and
antiapoptotic signals. In this decisive life or death choice, the
transcription factor NFkB has emerged as a prosurvival actor in
most cell types [4,5]. Early microarray analysis of radiation
exposed human cells revealed several novel radiation-induced
genes, including FRA1 and ATF3, which encode important
transcription factors and require functional p53 for radiation
responsiveness [6]. Signaling through MAP kinase pathways can
also contribute to the molecular response to radiation exposure.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39426It has been shown that ERK 1/2 pathway has been involved in
the upregulation of EGR-1 [7] and VEGF [8] expression in the
presence of ionizing radiation mediated by activator protein
1(AP-1) which may lead to further neovascularization and
proliferation of glioblastoma cells.
The complexity of signaling that occurs following exposure to
IR allows flexibility in determining the ultimate fate of damaged
cell or tissue. Competition between p53 and NFkB has been
shown to sway the balance between apoptosis and survival of
irradiated cell. The NFkB-inducing kinase (NIK) is a mitogen-
activated protein kinase kinase kinase that potently induces NFkB.
Although the upstream receptor remains uncertain, downstream
NIK signaling leads to marked activation of the IkB kinases (IKKs)
[9], which phosphorylate IkBa, leading to its rapid ubiquitination
and degradation by the 26S proteasome. Inactive NFkB/IkB may
continuously shuttle between the cytoplasm and nucleus; however,
degradation of IkBa allows DNA binding by the liberated NFkB
complex and promotes target gene expression [10–12]. NFkB
plays a key role in cytokine and growth factor signaling, serving to
regulate the expression of panoply of genes that mediate
inflammatory, anti-apoptotic, and proliferation or differentiation
signaling [13,14].
Hoechst 33342 had been shown to protect genomic DNA
against radiation-induced damage. It was reported that the
radioprotective activity may be improved by the addition of
electron-donating substituents to the ligand [15–17]. On the
other hand, inhibition of topoisomerase as well as chromatin
structure dependent DNA repair by Hoechst 33342 lead to a
higher level of residual DNA damage, resulting in a higher level
of cytogenetic damage, cell cycle perturbations, and genomic
instability, thereby enhancing cytotoxicity [18]. Therefore,
development of DNA binding ligands that afford a radioprotec-
tive effect without causing mutagenic and cytotoxic effects can
play a significant role in biological radioprotection. Here we
report the radioprotective effects of two minimally cytotoxic
synthetic disubstitutedbenzimidazoles-DMA (Fig. 1A) and TBZ
(5-{4-methylpiperazin-1-yl}-2-[29{299-(4-hydroxy-3-methoxyphe-
nyl)-599-benzimidazolyl}-59-benzimidazolyl]. Their radiomodify-
ing effects were investigated on BMG1, a human glioma cell line
exposed to Co-60 gamma irradiation by determining cell survival
and cell proliferation compared with that of the parent
compound, Hoechst 33342. Results from radiation induced
growth inhibition showed that DMA & TBZ afforded 84% and
100% radioprotection respectively in human brain glioma cells
(BMG1 cells) [19]. Both ligands quench free radicals in isolated
free radical system suggesting their dual mode of action against
radiation induced damage to DNA. Our data indicate a 2-fold
protection by DMA [20], which acts through altering DNA
structure and free radical quencher both, as compared to
Hoechst, which had shown free radical quenching only. The cell
survival assay on four cell lines; human epithelial cancer cells
(Hela), human breast cancer cell line (MCF7), human glioma cell
line (U87), Human embryonic kidney cell line (HEK) was done
previously in our laboratory [21].
Herein, we sought to gain insights on the enhanced
radioprotective efficacy and noncytotoxicity of DMA (Fig. 1A).
Microarray hybridization and protein expression analysis by 2D
PAGE revealed large number of genes that are regulated in
response to DMA and/or ionizing radiation. Real time
quantitation of the identified proteins and headers confirmed
differential regulation. On the basis of our results we propose the
involvement of NFkB inducing kinase as the regulator of gene
expression modulation in response to DMA and/or ionizing
radiation.
Results
DMA Exerts Reduced Cytotoxicity
In our earlier publications, we have already established that
DMA is a radioprotector and it protects the human brain glioma
cells (BMG1) from radiation and it is less cytotoxic to several
cancer as well as transformed cell lines [19]. In view of above, it
became imperative to evaluate the cytotoxicity of DMA in normal
cells. We examined the cytotoxicity of DMA in primary human
dermal fibroblasts (HDF) and near normal mammary epithelial
cells (MCF10A) over a wide range of concentrations (0.1–150 mM)
up to 72 h post DMA treatment. Interestingly, the IC50 of DMA
in HDF and MCF10A could not be determined up to 72 h
suggesting that DMA is less cytotoxic to normal cells in
comparison to cancerous cells and can be developed as safe
therapeutic agent. In addition to it we have measured the toxicity
of DMA in U87 cell line also as it possess wild type p53 status and
have been taken up as a system for studying irradiation and
cytoprotective effects previously.The half maximal inhibitory
concentration (IC50) of DMA was found to be 100 mMa t2 4h
in U87 cells (Fig. 1B, C, D).
Differential Gene Expression in Response to DMA and
Radiation Treatment in U87, Human Glioma Cells
PANTHER gene expression tool was used to classify the
differentially expressed genes affected by the three different
treatment conditions in U87 human glioma cells, when compared
to non-treated control, into specific pathways (Table 1). A total of
30 pathways were found to be differentially expressed in U87 cells
treated with DMA, radiation and DMA+radiation (P,0.005). In
DMA treated U87 cells, higher percentage of genes modulated
were from the General transcription by RNA polymerase I (45%),
General transcription regulation (8.82%), Cell cycle (13.636%),
Transcription regulation by bZIP transcription factor (9.43%),
Insulin/IGF pathway-MAP kinase cascade (14.28%), Insulin/IGF
pathway-protein kinase B signaling cascade (13.48%) pathways as
compared to radiation alone. On the contrary, higher percentages
of genes modulated in the radiation treated U87 cells were from
oxidative stress response (11.66%), p53 pathway (10.619%), p53
pathway feedback loops 2 (11.538%) as compared to DMA or
DMA+ radiation with respect to control (Untreated cells).
From these pathways, a number of representative differentially
expressed genes identified are given in Table 2. Two important
NFkB signaling related genes - CREB3L4 and TRERF, were
induced in DMA treated cells. Other related transcription factors-
HIF1A, ASCC3 and CREBBP were found to be upregulated in
response to DMA treatment. MAP3K14 (NFkB inducing kinase)
was upregulated in DMA and DMA + radiation treated cells.
2D PAGE Reveals Modulation of Protein Expression in
Response to DMA and Radiation Treatment
A total of 19 proteins were identified and observed as
differentially regulated (upregulated or downregulated) in response
to DMA, radiation and DMA+ radiation with respect to control
(untreated cells) by 2D PAGE and ESI-MS/MS analysis (Fig. 2
and Table S1, S2).
These differentially expressed proteins belonged to four
different categories- chaperones and folding catalysts (HSP70,
CALR, TRX, PRX2, PDIA3); structural proteins (UBCEP80,
H2B1, ACTG, TPM4, VIM, FABPE); Single stranded nucleic
acid binding proteins (NPM1,PCBP1); Glycolytic pathway en-
zymes (PGM, ENO1,TPI, PARK7,NACA). Since most of these
proteins are interacting partners, a pathway construction was
attempted by online available sources (KEGG, NCBI). This
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MAP3K3, MAP3K7 & and MAP3K14 (Fig.3).
Relative Quantitation of Gene Expression of 2D PAGE
Identified Proteins by Real Time PCR
Out of the total genes identified from 2D page, a total of 5 genes
of MAP kinase pathway were quantitated by RT PCR. Out of the
five MAP kinase pathway genes, YWHAZ and MAP3K14 (NIK)
were found upregulated in response to DMA and DMA +
radiation treated cells. However, no effect was observed in
response to irradiation only. In the case of MAP3K3, MAP3K7
and MAP3K10, no significant differential expressions were
observed in all the treatment conditions. Similarly, NFkB (RelA
subunit) was observed to be differentially regulated in DMA and
DMA+ radiation treated cells in comparison to radiation alone
(Fig. 4).
DMA Potentiates NFkB- Inducing Kinase Mediated
Activation of IKKa and IKKb
The phosphorylation of both IKKa and IKKb were not
observed in control and radiation treated U87 cells, transfected
with control siRNA through western blot experiments (Fig.5).
However, in response to DMA and DMA + radiation, phosphor-
ylated IKKa was observed. Phosphorylated IKKb was also
observed albeit to a weaker extent (Fig. 6). Over expression of
NFkB- inducing kinase by transfecting U87 cells with p3XFLAG
CMV10 NIK plasmid potentiated the activation of IKKa and
IKKb in DMA treated cells (Fig. 7). Minimal level of IKKa
phosphorylation was observed in control cells, with no phosphor-
ylation of IKKb being detected. In radiation treated cells,
activation of both IKKa and IKKb was not observed. In response
to DMA and DMA+radiation, phosphorylated form of both IKKa
and IKKb was detected. In all the samples, detection of IkBa was
abrogated concurrent with observation of phosphorylated form of
either IKKa or IKKb (Fig.7). Transfection of U87 cells with
siRNA-NIK and subsequent knock down of NFkB- inducing
kinase expression gave a different response (Fig.6). In all the
treated samples, phosphorylated form of both IKKa and IKKb
was not observed. However, total IKKa, IKKb and IkBa were
detected at all the time points. There was no change observed in
total protein levels of both IKKa and IKKb, following DMA and
TNF-a stimulation.
siRNA -NIK Knock down Abrogates DMA-induced
Radioprotection in Transfected Cells
In vitro cell proliferation assay was used to study radioprotective
ability of DMA in siRNA-NIK transfected and control siRNA
transfected cells with or without radiation [22]. As shown in Fig. 8,
the percentage of radioprotection by DMA in control siRNA
transfected cells with respect to drug only control at 24, 48 and
Figure 1. Effect of DMA on survival of HDF, MCF10A and U87 cell lines. (A) Structure of the DNA minor groove binding ligand DMA –5-(4-
methylpiperazin-1-yl)-2-[29-(3,4-dimethoxyphenyl)-59-benzimidazolyl] benzimidazole.(B) Effect of varying concentrations of DMA on metabolic
viability studied by MTT assay in exponential growing HDF,MCF10A and U87 cells at 24 h, (C) At 48 h (D) At 72 h.Values are mean (6SD) of three
independent experiments.Statistical significance by T-test p,0.05.
doi:10.1371/journal.pone.0039426.g001
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transfected cells the percentage of radioprotection by DMA was
15%, 18% and 10% at 24, 48 and 72 h respectively.
DMA does not Perturb Cell Cycle
To further study the effect of DMA on cell cycle, we examined
the cell cycle in control siRNA transfected as well as siRNA-NIK
transfected U87 cells. We have observed normal cell cycle in
control siRNA treated cells, whereas cells did show a strong G2
check point after irradiation alone. There was clear G2 phase
accumulation (18.9%) at 6 h after exposure to 8.5 Gy, which was
increased till 18 h (34.5%), came near to normal at 24 h (22.3%)
(Fig. 9E, G). There was no strong/significant G2 check point
observed after DMA (50 mM) treatment in control siRNA treated
cells, but in DMA + radiation treated cells we have observed a
significant G2-M (43.5%) arrest than the irradiated cells (34.5%) at
18 h(Fig. 9E, G). The delay in cell cycle progression is probably
exploited by the cells to perform DNA repair, and as a
consequence to reduce the adverse effects of radiation, such as
cell killing and induction of mutations. The cell cycle analysis of
siRNA-NIK transfected cells also showed strong G2 check point
after radiation treatment (11.9% at 0 h, 13.3% at 3 h, 18.6% at
6 h, 30.3% at 12 h, 43.6% at 18 h and 29.7% at 24 h), whereas
the G2 check point response in DMA + radiation treated cells was
almost similar to radiation only treated group reassuring that the
activity of DMA is diminished in NIK abrogated cells (Fig 9. F, H).
The Annexin V assay showed lot of early and late apoptotic
events in radiation treated U87 cells upto 24 h. The percentage
apoptosis kept increasing in radiation treated cells till 24 h in a
significant manner. In DMA + radiation treated cells the total
(35% at 3 h, 30% at 6 h and 18% at 24 h) of early and late
apoptotic cells were observed less in comparison to radiation
treated cells only (45% at 3 h, 6 h and 24 h data not shown) (Fig 9.
A, C). But in NIK knocked down cells the apoptotic events were
almost similar in radiation (60% at 3 h, 6 h and 24 h data not
shown) as well as DMA + radiation treated cells (58% at 3 h, 52%
at 6 h, and 52% at 24 h), suggesting that NIK plays a role in the
radioprotection activity of DMA. (Fig 9. B, D). Recently, there is a
report where role of NIK was implicated in cell survival,
supporting our observation [23].
DMA Affects NFkB Activation in a dose Dependent
Manner
TNF-a induced NFkB dependent reporter gene transcription
assay showed no activation of NFkB in control and radiation
treated cells. To confirm that the activation of NFkB was
specifically caused by DMA, a series of concentration of DMA
(0, 10, 25, 50 mM) was used in cells co-transfected with pNFkB-
Luc (0.2 mg/well) and pRenilla (0.02 mg/well) and induced with
20 ng/ml TNF-a (Fig. 10). The results showed that NFkB
activation was promoted in a dose-dependent manner by DMA.
From 10 to 50 mM, a concentration dependent increase in
induction of NFkB activation was observed in response to DMA.
Higher induction of NFkB activation was observed in 50 mM
DMA treated cells exhibiting a fold change of 3.62. However,
NFkB activation was abrogated in U87 cells following irradia-
tion. In DMA + radiation treated cells, activation of NFkB was
again dose dependent with higher activation occurring in 50 mM
+ radiation treated cells i.e.; 5.77 fold as compared to control
cells.
Identification of NFkB Inducing Kinase as the Candidate
Gene
From microarray hybridization and data analysis (Table 2),
three important NFkB signaling related genes - CREB3L4,
ASCC3 and TRERF were induced in DMA treated cells. It has
been reported that CREB3L4 is a bZIP transcription factor that
localizes to the membrane of endoplasmic reticulum and plays a
role in cell homeostasis. It also has transcriptional activation
activity from NFkB regulatory elements [24]. Another related
transcription factor-ASCC3 was found to be upregulated in
response to DMA treatment. ASCC3 has been reported to exist as
a steady-state complex associated with three polypeptides, P200,
P100, and P50, which stimulates transactivation by serum
response factor (SRF), activating protein 1 (AP-1), and Nuclear
factor kappaB (NF-kappaB) through direct binding to SRF, c-Jun,
p50, and p65; and relieves the transrepression between nuclear
receptors and either AP-1 or NF-kappaB. TRERF is another
important transcription factor that has been observed to interact
Table 1. List of pathways and number of genes in each
pathway identified in U87 cells in three different treatment
conditions DMA (50 mM), radiation (8.5 Gy) and DMA+
radiation (50 mM +8.5 Gy) after 4 h by Microarray
hybridization studies.
Pathways DMA Radiation DMA+Radiation
VEGF signaling pathway 14 6 10
Oxidative stress response 5.5 13 7.4
FAS signaling pathway 14.6 17.4 9
Glutamatereceptor group II pathway 14 8.8 8.8
PDGF signaling pathway 13.8 10.5 13.5
Cadherin signaling pathway 13 12 11
Nicotinic acetylcholine receptor
signaling
14.2 10 15
IGF pathway-protein kinase B
signaling
14.2 10 10
IGF pathway-MAP kinase cascade 15 12.3 9
Ras pathway 14.8 4 8
Ubiquitin proteosome pathway 15 15 15
p53 pathway feedback loops 2 10 12 6
bZIP transcription factor 10 4.6 4.6
Interleukin signaling pathway 11.2 7.2 8
TGF-beta signaling pathway 14.8 9 8
p53 pathway 5.4 10.8 7.5
PI3 kinase pathway 10.6 6 6.4
Salvage pyrimidine ribonucleotides 22 14.4 7.5
Cell cycle 14 5 12.2
Wntsignaling pathway 10.6 10.6 11
Apoptosis signaling pathway 5 11 8
Integrin signaling pathway 10.6 6 6
General transcription regulation 9 5 6.4
Notch signaling pathway 7 4.6 4.6
Cytokine signaling pathway 10.4 5.7 6
Synaptic vesicle trafficking 21.4 18 15.8
DNA replication 28 14.6 14.6
FGF signaling pathway 6.2 3 2
General transcription 45 15 35
doi:10.1371/journal.pone.0039426.t001
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radiation (50 mM+8.5 Gy).
Accession
number
Gene
symbol Gene Name Function DMA Radiation
DMA+
Radiation
NM_130898 CREB3L4 cAMP responsive element binding protein
3-like 4
regulation of transcription,
DNA-dependent
4.03 1.55 1.65
AF297872 TRERF1 transcriptional regulating factor 1 Transcription regulation 4.9 0.54 6.45
NM_005902 ASCC3 Activating signal cointegrator 1 Complex
subunit 3
Transcription regulation 5.290 0.86 1.68
AC004760 CREBBP CREB binding protein mRNA transcription
regulation
2.18 0.18 1.92
BC012527 HIF1A hypoxia-inducible factor 1, alpha subunit Transcription activation 0.981 0.909 5.075
AC008105 HIF!A Mitogen activated protein kinase
kinasekinase 14
Positive regulation of
NFkB cascade
4.236 0.456 1.375
NM_004045 ATOX1 ATX1 antioxidant protein 1 homolog (yeast) response to oxidative stress 0.137 0.82 0.11
NM_012111 AHSA1 AHA1, activator of heat shock 90 kDa protein
ATPase homolog 1(yeast)
response to stress 0.146 1.5 0.17
NM_005742 PDIA6 Protein disulfide isomerase family A, member 6 protein folding 0.15 0.84 0.15
BC015484 CALB2 calbindin 2, 29 kDa (calretinin) calcium ion binding 0.131 1.07 0.12
NM_007236 CHP calcium binding protein P22 calcium ion binding 0.52 1.05 0.086
NM_002155 HSPA6 heat shock 70 kDa protein 7 (HSP70B) unfolded protein response 0.441 0.91 0.493
NM_006597 HSPA8 heat shock 70 kDa protein 8 unfolded protein response 0.327 0.74 0.474
BC024034 HSPA9 heat shock 70 kDa protein 9 (mortalin) unfolded protein response 0.395 0.93 0.59
NM_005347 HSPA5 heat shock 70 kDa protein 5
(glucose-regulated protein 78 kDa
unfolded protein response 0.06 0.77 0.118
NM_002157 HSPE1 heat shock 10 kDa protein 1 (chaperonin 10) unfolded protein response 1.07 3.74 1.03
NM_145046 CALR3 calreticulin 3 unfolded protein binding 1.28 5.09 1.04
BT019740 PRDX1 peroxiredoxin 1 peroxiredoxin 1 0.97 1.22 0.002
BT020007 PRDX3 peroxiredoxin 3 redox regulation 0.66 0.70 0.169
NM_012473 TXN2 thioredoxin 2 response to hypoxia 1.49 1.32 0.067
NG_005218 HSP90AA3P heat shock 90 kDa protein 1, alpha-like 1 Chaperone 1.43 1.74 0.071
NM_006993 NPM3 nucleophosmin/nucleoplasmin, 3 nucleic acid binding 0.20 1.27 0.105
BC009623 NPM1 nucleophosmin (nucleolarphosphoprotein
B23, numatrin)
nucleic acid binding 0.27 1.55 0.16
NM_006472 TXNIP thioredoxin interacting protein response to oxidative stress 0.18 1.29 0.202
NM_001540 HSPB1 heat shock 27 kDa protein-like
2 pseudogene; heat shock 27 kDa protein
unfolded protein response 0.44 1.66 0.464
NM_022121 PERP PERP, TP53 apoptosis effector induction of apoptosis 0.28 3.87 0.244
BC022307 ATM similar to Serine-protein kinase ATM (Ataxia
telangiectasia mutated)
DNA Repair 0.69 0.84 0.194
NM_001924 GADD45A growth arrest and DNA-damage-inducible, alpha DNA Repair 0.329 1.24 0.64
NM_015675 GADD45B growth arrest and DNA-damage-inducible, beta DNA Repair 0.113 0.64 0.378
NM_006705 GADD45G growth arrest and DNA-damage-inducible,
gamma
DNA Repair 0.177 0.94 0.206
NM_007233 TP53BP1 TP53 activated protein 1 Response to DNA damage 0.119 0.783 0.51
NM_005657 TP53AP1 TP53 binding protein 1 Response to DNA damage 0.14 2.41 1.13
NM_006034 TP53I11 TP53 inducible protein 11 Response to stress 0.203 1.06 0.69
NM_002578 PAK3 p21 (CDKN1A)-activated kinase 3 protein serine/threonine
kinase activity
0.154 1.16 0.17
NM_020168 PAK6 p21 (CDKN1A)-activated kinase 6 protein serine/threonine
kinase activity
0.22 1.22 0.21
NM_004964 HDAC1 histone deacetylase 1 regulation of transcription,
DNA-dependent
0.216 0.69 0.35
(D=50 mM DMA treated cells, R=8.5 Gy irradiated cells, D+R=50mM DMA+8.5 Gy treated cells; Fold change values in red indicate upregulation in comparison with
control untreated cells (2 fold and above); Fold change values in green indicate downregulation in comparison with untreated control (0.5 fold and.
doi:10.1371/journal.pone.0039426.t002
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activation of CYP11A1. Expression of HIF1A was found to be
increased in DMA + radiation treated cells. It was reported that
activation of HIF1A requires recruitment of transcriptional
coactivators such as CREBBP and EP300.It also binds to core
DNA sequence 59-[AG] CGTG-39 within the hypoxia response
element (HRE) of target gene promoters. Since CREBBP is a
coactivator of P300/CREB, increase in its expression would
oppose the proapoptotic function of p53. Expression of HIF1A
[25] was increased in DMA + radiation treated cells. Hence, we
observed upregulation of NFkB inducers and effectors from
microarray and real time PCR results. The key signaling molecule
observed as upregulated was NFkB inducing kinase, which
subsequently leads to mobilization of NFkB from cytosol to the
nucleus thereby activating the nuclear targets and hence the
transactivation of downstream genes. Thus, activation of NFkB
inducing kinase in DMA treated cells perhaps may explain
counteraction of radiation- induced damage.
Discussion
On the basis of microarray hybridization and data analysis of
differentially regulated genes following pathways were observed to
bedifferentiallyregulatedonDMAandionizingradiationtreatment
inU87cells–Apoptosispathway,Chaperonesandfoldingcatalysts,
Transcription regulator, oxidative stress response cell cycle, signal
transduction and p53 pathway. Two prominent NFkB signaling
related genes - CREB3L4 and TRERF were induced in DMA
treatedcells.WeobservedexpressionofanumberofNFkBsignaling
related genes (MAP3K14, CREBBP, CREB3L4, TRERF, ASCC3
and HIF1A) to be regulated in response to DMA from Microarray
hybridization and data analysis. Thus, the concerted action of
CREB3L4,TRERF,ASCC3andHIF1AinducesCREB/p300and
NFkB resultsinoppositionofproapoptotic responseandincreasein
transcriptional activation.
Regulation of MAP3K14, CREB3L4, ASSC3, HIF1A points
towards the activation of the NFkB mediated signaling pathway.
Marked increase in NFkB activation in DMA treated cells
indicates promotion of cell survival and proliferation. Simulta-
neously, downregulation of HSP70, stress responsive gene as
observed in cells treated with DMA could further lead to reduction
in inhibition of the NFkB inducing kinase, since HSP70 blocks
NFkB activation via inhibition of both I kappa B kinase (IkK)
activation and subsequent degradation of I kappa B alpha (IkBa)
[26,27]. Induction of NFkB inducing kinase subsequently leads to
Figure 2. One representative image of 2D PAGE of the
proteome of U87, cells in response to DMA, radiation and
DMA+radiation treatment. Protein spots showing differential
expression in the DMA, radiation and DMA+ radiation at 4 h time
point, an average of three replicates (data derived from replicate wells)
are annotated with arrows and numbers. The numbers given in this
figure denote the 19 differentially expressed proteins identified by 2D
PAGE and ESI-MS/MS analysis. The serial numbers 1–19 in table S1
denote the protein spots numbered in Figure 2. The left hand side spots
are of protein marker.
doi:10.1371/journal.pone.0039426.g002
Figure 3. Pathway construction based on the proteins identified from 2D PAGE and ESI-MS/MS Analysis. Genes/proteins identified from
proteomic data analyses were categorized into pathways based on NCBI, OMIM, KEGG and Gene Cards. Colour boxes represent the proteins identified
by ESI-MS/MS- chaperones and folding catalysts (HSP70, CALR, TRX, PRX2, PDIA3); structural proteins (UBCEP80, H2B1, ACTG, TPM4, VIM, FABPE);
Single stranded nucleic acid binding proteins NPM1,PCBP1); Glycolytic pathway enzymes (PGM, ENO1,TPI); PARK7,NACA. Blue boxes indicate
interacting partners not identified by ES-MS/MS but are common between the identified proteins as interacting partners. Red arrows indicate that the
proteins identified belonging to common categories and possessing common interacting partners converge onto MAPK signal transduction pathway.
doi:10.1371/journal.pone.0039426.g003
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activating the nuclear targets and hence the transactivation of
downstream genes. This as an effect could result in the suppression
of misfolded protein response, apoptosis and regulation of gene
expression to ensure enhanced cell survival (Fig. 11).
In addition following p53 pathway genes were downregulated in
DMA treated cells- PERP,ATM,GADD45A,GADD45B,-
GADD45G,TP53BP1,TP53AP1,TP53I11,PAK3,PAK6,HDAC1.
In cells treated with DMA alone, we observed simultaneous
activation of NFkB and downregulation of p53 responsive genes
(Table 2). p53 is generally a proapoptotic transcription factor,
while NFkB promotes resistance to programmed cell death. The
NFkB had an ability to suppress p53 transactivation and thus
inhibitthe transcriptionally dependent induction of apoptosis by
Figure 4. Relative quantitation of gene expression for MAPK pathway genes in U87 cells. U87 cells were treated with 50 mM DMA and/or
8.5 Gy ionizing radiation. RNA samples were prepared 4 h after treatments. YWHAZ (14-3-3 zeta), MAP3K3 (Mitogen activated protein kinase
kinasekinase 3), MAP3K7 (Mitogen activated protein kinase kinasekinase 7), MAP3K14 (Mitogen activated protein kinase kinase 14), MAPK10 (Mitogen
activated protein kinase 10) and NFkB (Nuclear Factor Kappa B/Rel A subunit) were quantitated by Real Time PCRusing RNA samples from U87 glioma
cell line. Values represent Mean6S.D.(*indicates statistical significance by T-test, *p,0.05).
doi:10.1371/journal.pone.0039426.g004
Figure 5. Effect of transfection with control-siRNA on the phosphorylation of IKKa and IKKb. U87, human glioma cells were transiently
transfected with control-siRNA. Cells were induced with 10 ng/ml TNF-a for 0,5,10,20,40,60 min and treated with DMA (50 mM) and/or irradiated at
8.5 Gy. Phosphorylation of IKKa, IKKb was observed in DMA treated cells, alone or in combination with IR.
doi:10.1371/journal.pone.0039426.g005
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understood as an increasingly common mechanism regulating
inducible gene expression. It has been shown that p53 and RelA
(NFkB) can bind p300 and CBP competitively, the answer may lie
in the utilization of different p300/CBP complexes, being used by
distinct subsets of DNA-binding proteins, thus functionally
separating them and limiting cross talk to certain regulatory
families of transcription factors [28,29].Hence, the activity of
NFkB may directly oppose the proapoptotic function of p53
activation through competition for the p300/CREB-binding
Figure 6. Effect of transfection with siRNA-NIK on the phosphorylation of IKKa and IKKb. U87, human glioma cells were transiently
transfected with siRNA-NIK. Phosphorylation of IKKa, IKKb was absent concurrent with equivalent expression of IkBa in response to both DMA and
radiation treatment.
doi:10.1371/journal.pone.0039426.g006
Figure 7. Effect of NFkB inducing kinase overexpression on the phosphorylation of IKKa and IKKb. U87, human glioma cells were
transiently transfected with p3XFLAG CMV10 NIK. Phosphorylation of IKKa, IKKb was advanced in NIK overexpressing cells as compared to siRNA
transfected cells in response to DMA treatment, alone or in combination with IR.
doi:10.1371/journal.pone.0039426.g007
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with DMA leads to activation of NFkB inducers and effectors and
provides comparatively enhanced radioprotective efficacy.
In cells treated with DMA alone, we observed simultaneous
activation of NFkB and CCNB2, CASP8, THBS1 and CCNG2 of
p53 pathway were downregulated. Similarly BAX, CDK4,
CCNG1, SESN1were found to be upregulated in DMA+
radiation treated U87 cells with no change in radiation alone. In
our earlier work, we had observed that DMA modulates radiation
damage to DNA through free radical quenching, which was
supported by observing regulation of a number of genes in
apoptotic pathway in U87 cell line. TNFRSR1A, CASP8,
PIK3R5, BCL1, CAPN1 were found to be downregulated in
DMA treated cells. Since these genes are the central components
of apoptotic response their downregulation in response to DMA
further implicates the absence of DNA damage. Thus, treatment
with DMA leads to activation of NFkB inducers and effectors and
provides comparatively enhanced radioprotective efficacy.
Figure 8. Radioprotection afforded DMA studied by proliferation kinetics assay in Control siRNA and siRNA-NIK transfectedU87
cells. (A) U87 cells (Control siRNA transfected) were treated with 50 mM DMA and 8.5 Gy Radiation. Post treatment cells were seeded in 6 well plates
seeded at 8000 cells/cm2, and their proliferation kinetics was studied at 24 h intervals following trypsinization and counting total cells per well using
a hemocytometer. (B) U87 Cells post siRNA-NIK oligonucleotide transfection were treated with 50 mM DMA and 8.5 Gy Radiation. Post treatment cells
were seeded in 6 well plates seeded at 8000 cells/cm2, and their proliferation kinetics was studied at 24 h intervals following trypsinization and
counting total cells per well using a hemocytometer. Values are mean (6SD) of three independent experiments.Statistical significance by T-test
p,0.05.
doi:10.1371/journal.pone.0039426.g008
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absence of activation of DNA damage responsive genes, and over
expression of signal transduction genes as well as transcription
regulation factors may be possible reasons behind the radiopro-
tective ability of this molecule as observed by attenuated DNA
damage at the cellular level.
A total of 19 proteins were identified as differentially expressed
and categorized into four pathways using KEGG-chaperones and
folding catalysts, structural proteins, single stranded nucleic acids
binding proteins and metabolic enzymes on the basis of 2D PAGE
analysis of U87 cells. Protein expression of five chaperones and
folding catalysts was observed to be altered- HSP70, CALR, TRX,
PRDX, and PDIA. A number of structural proteins were also
identified as differentially expressed- UBCEP80, H2B1, ACTG,
TPM4, VIM and FABPE. Two single stranded nucleic acids
binding proteins-NPM and PCBP1 were found to be upregulated
in radiation treated cells, however, in cells treated with DMA only,
were found to be normally expressed. Enzymes belonging to the
glycolytic pathway found to be differentially regulated were-
PGAMB, ENO1 and TPI. Pathway construction using online
available resources, on the basis of identified proteins and their
interacting partners led onto the identification of the headers
(MAP3K14, MAP3K7 and MAP3K3) that could be involved in
modulation of radiation response by DMA in U87 cells (Fig. 3).
Figure 9. DMA attenuates radiation induced apoptosis in U87 through NIK. (A) Apoptosis analysis of control siRNA transfected U87 cells at
3 h, 6 h in different treatment condition i.e. 50 mM DMA, radiation (8.5 Gy) and DMA (50 mM) + Radiation (8.5 Gy). Percentage of apoptosis is defined
by % of cells that are Annexin V
+ and Annexin V
+PI
+. (B) Apoptosis analysis of siRNA-NIK transfected U87 cells at 3 h, 6 h in different treatment
condition i.e. 50 mM DMA, radiation (8.5 Gy) and DMA (50 mM) + Radiation (8.5 Gy). Percentage of apoptosis is defined by % of cells that are Annexin
V
+ and Annexin V
+PI
+. (C) Percentage of Annexin V
+ and Annexin V
+PI
+.positive cells in control siRNA transfected U87 cells at, 3 h,6 h, and 24 h in
different treatment condition i.e. 50 mM DMA, radiation (8.5 Gy) and DMA (50 mM) + Radiation(8.5 Gy). (Data Not shown for 6 h and 12 h for only
DMA and only radiation treatment condition). (D) Percentage of ofAnnexin V
+ and Annexin V
+PI
+.positive cellssiRNA-NIK transfected U87 cells at 3 h,
6 h, and 24 h in different treatment condition i.e. 50 mM DMA, radiation (8.5 Gy) and DMA (50 mM) + Radiation (8.5 Gy).(Data Not shown for 6 h and
12 h for only DMA and only radiation treatment condition). (E) Time course graphs showing the progression of cell cycle of control siRNA transfected
U87 cells at 0, 3, 6, 12, 18 and 24 h in different treatment condition i.e. 50 mM DMA, radiation (8.5 Gy) and DMA (50 mM) + Radiation(8.5 Gy). (F) Time
course graphs showing the progression of cell cycle of siRNA-NIK transfected U87 cells at 0, 3, 6, 12, 18 and 24 h in different treatment condition i.e.
50 mM DMA, radiation (8.5 Gy) and DMA (50 mM) + Radiation(8.5 Gy). (G) Cell cycle progression of control siRNA transfected U87 cells showing % G2-
M fraction at 0, 3, 6, 12, 18 and 24 h in different treatment condition i.e. 50 mM DMA, radiation (8.5 Gy) and DMA (50 mM) + Radiation(8.5 Gy). (H) Cell
cycle progression of siRNA-NIK transfected U87 cells showing % G2-M fraction at 0, 3, 6, 12, 18 and 24 h in different treatment condition i.e. 50 mM
DMA, radiation (8.5 Gy) and DMA (50 mM) + Radiation(8.5 Gy).
doi:10.1371/journal.pone.0039426.g009
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genes. 19 genes were chosen from 2D PAGE results and two more
i.e.; MAP3K14, header of the pathway constructed by us on the
basis of 2D PAGE results, and NFkB a downstream gene of
MAP3K14 were also included for real time study. Relative
quantitation of above genes(data not shown for all genes) suggested
modulation of a number of genes - HSP70, TXN, PDI, CALR,
PRDX, YWHAZ, NPM1, PCBP1, MAP3K14, NFkB, H2B1.
RT PCR experiments validated modulation of YWHAZ,
MAP3K14, NFkB in MAP kinase pathway genes in all treatment
conditions (Fig. 4). YWHAZ belongs to the family of 14-3-3
proteins that are pivotal regulators of intracellular c-Abl localiza-
tion and of the apoptotic response to genotoxic stress [30].
Upregulation of this gene in response to DMA, both alone and in
combination with IR shows regulation of cell cycle machinery by
DMA. NFkB is known as a proinflammatory transcription factor
and is now confirmed as an antiapoptotic and prosurvival force in
the most cell types [31–33]. This gene was upregulated in DMA
and DMA + radiation treated cells, thus implicating the activation
of pro-survival genes in response to DMA. MAP3K14, an
upstream kinase was upregulated in DMA and DMA+ radiation
treated cells. It has been reported that MAP3K14 binds to Traf2
and stimulates NFkB activity [34–36].
Amifostine, along with other thiol-containing drugs, such as N-
acetylcysteine (NAC), mesna, and oltipraz, which have been
approved for clinical use as radioprotector, are capable of
participating in intracellular reductive/oxidative processes that
have broad clinical implications. These include effects on the
activation of redox-sensitive transcription factors, alteration of
gene expression, and modification of protein activities. Amifostine,
NAC and oltipraz activate the redox-sensitive transcription factor
NFkB in the absence of oxidative stress–inducing agents [37–41].
DNA-binding motifs for NFkB were found in the promoter
regions of more than 150 genes, many of them involved in
inflammatory processes and the survival response [14]. NFkBi sa n
inducible transcription factor that plays an essential role in the
expression of a number of gene families that include cytokines and
their receptors, cell adhesion molecules, growth factors, and
antioxidant genes [42]. A number of reports have described the
activation of NFkB by reducing agents, when present at mM
concentrations, such as NAC, dithiothreitol, 2-mercaptoethanol 2-
ME, oltipraz, and amifostine [38–40,43]. It has been reported that
exposure of glioma cells to mM concentrations of WR-1065
significantly protected these cells from the cytotoxic and muta-
genic effects of ionizing radiation [44,45]. The Putrescine,
spermidine, and spermine have each been reported to participate
in the activation of NFkB and to enhance its binding to nuclear
response elements (NREs) [46]. The underlying mechanism of
action is not attributed to changes in oxidative stress, but rather to
the ability of these positively charged molecules to activate NFkB
and affect structural/conformational changes in DNA that
facilitate an enhanced binding of NFkB to its NRE sequences.
On the basis of above results, we identified NFkB inducing
kinase as the candidate gene affected by DMA. Western blots
results suggested that DMA affects NIK mediated NFkB
activation. In cells overexpressing NIK, DMA promoted activa-
tion and phosphorylation of IKKa and IKKb, although extent of
phosphorylation of IKKb was weaker than IKKa. Activation of
IKKa and IKKb in DMA treated samples, alone or in
combination with radiation, was concurrent with degradation of
IkBa. As compared to cells treated with control-siRNA, activation
was advanced in time in cells over expressing NIK. On the
contrary, cells in which the NIK expression was knocked down by
siRNA-NIK, no activation and phosphorylation of IKKa and
IKKb was observed in response to DMA, alone or in combination
with IR. Luciferase reporter assay confirmed dose dependent
induction of NFkB activation.
Biochemically the apoptotic process is first recognized by
alterations of surface lipid composition, in that, phosphotidylser-
ine, which is normally on the inner leaflet of plasma membrane,
translocates to the outer leaflet, which can be easily measured by
fluorescent labeled Annexin V binding assay. An impermeable dye
propidium iodide, cannot enter the cells unless the cells are under
late apoptosis, when membrane permeability is compromised.
This can be quantified in large population of cells by flow
cytometry. The control siRNA (untreated) cell culture contained
very few apoptotic cells (6.5%) (Data not shown), which were
assigned as the background cell death due to stress during normal
cell culture. We found that in DMA (50 uM ) treated U87
transfected with control siRNA, resulted in 9% early apoptotic
cells within 24 h, but radition (8.5 Gy ) treated cells showed 45%
early apoptotic cells within 3 h which were reduced to 35% at 3 h,
30% at 6 h and 18% at 24 h in DMA + radiation treated cells.
The U87 cells transfected with siRNA-NIK, showed 60%
apoptotic cells after irradiation (8.5 Gy) at 3 h time point, which
were consistant to 58% at 3 h, 52% at 6 h and 52% at 24 h in
DMA + radiation treated siRNA-NIK transfected cells. The
Figure 10. Luciferase assays for NFkB activation in U87 cells.
Cells were co-transfected with pNFkB-Luc and pRenilla. After 24 h, cells
were irradiated (8.5 Gy) with or without DMA treatment (50 mM) and
stimulated with TNF-a (20 ng/ml) for 4 h prior to cell lysis. Luciferase
activity was determined to quantify NFkB transcription activity. Relative
Luciferase activity (RLA) for NFkB activation was increased in DMA
treated cells compared with irradiated or control cells. The triplicate
samples were used and the data was presented as mean6SD from
three independent experiments. (*indicates statistical significance by T-
test, *p,0.00001).
doi:10.1371/journal.pone.0039426.g010
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events in U87 cells, hence DMA can be proposed as a safe
molecule. This result is in concurrence of our earlier results in
which DMA was observed less cytotoxic in comparison to parent
molecule Hoechst 33342, a free radical quencher, no significant
DNA damage was observed through comet assay [20].
We observed higher RQ value of NFkB in DMA treated cells as
compared to DMA+radiation treated cells in RT-PCR. However,
in luciferase reporter assay higher activation of NFkB was
observed in DMA+radiation treated cells as compared to DMA
treated cells in luciferase reporter assay. From a RT-PCR
experiment only the transcript level is measured, but luciferase
reporter assay takes into account promoter binding dependent
activation and/or post transcriptional modification or transactiva-
tion. Hence, reporter assay is a more direct study of the NFkB
protein level in response to DMA and/or radiation treated cells.
Therefore, ultimately we observed higher activation of NFkBi n
DMA + radiation treated cells.
We observed absence of IKKa and IKKb activation and
phosphorylation as well as subsequent NFkB activation in
irradiated cells. Reactive oxygen species (ROS) increase first
promotes NFkB activation by triggering NIK activation, which
usually leads to prosurvivaltranscriptional events. However, as
ROS become overwhelming, the nuclear environment is shifted
from reductive to oxidative, which inhibits activation of NFkB and
other transcriptional factors by preventing them from binding to
DNA. As a consequence, the prosurvival transcription activity is
abolished [47]. This increased ROS then leads to shift in survival/
death control.
We examined the effect of NIK inhibition by siRNA on the
proliferation of U87 cells in DMA treated cells in the presence and
absence of radiation. We observed a significant decrease of 36% in
Radiation protection in siRNA- NIK treated cells as compared to
control siRNA treated U87 cells at 24 h. The complete absence of
radioprotection was not observed as we had already established
that DMA, has a dual mode of action against radiation [20], it also
acts as free radical quencher. The parent analogues Hoechst
33258 & 33342 were well identified as free radical quencher,
generated directly or indirectly by IR [18,48].
These results are in the agreement with our microarray, real
time and western blot results suggesting that the radioprotective
effect of DMA is NIK mediated. Collectively, our data suggests
that, one of the primary targets of DMA is NIK. We may conclude
that radioprotective effect of DMA is due to NIK mediated NFkB
activation leading irradiated cells to antiapoptotic and prosurvival
pathway, one of the plausible mechanisms of action of DMA as a
radioprotector.
Amifostine is converted into active form in normal cells by
alkaline phosphatase which is inactive in an acidic environment
of tumors making it a selective drug for normal cells. The major
side effects of amifostine are transient hypotension, flushing,
somnolence, metallic taste and transient hypocalcaemia. Also
amifostine effect will be reduced in tumor cells due to hypoxia
state [49]. On the contrary, our molecule DMA has dual mode
of action i.e.;free radicals quenching and binding to DNA which
makes it a better molecule [19]. Our cytotoxicity data suggest
that DMA is more toxic to cancerous cells then normal cells.
Abnormal vasculature of cancerous cells can be one of the
possible modes of differential uptake of DMA in cells. Thus our
correlation of NIK and DMA in U87 cells can be further
elucidated for clinical importance in normal cell lines. NIK/IKK
mediated NFkB activation is at a pivotal role for promoting pro-
Figure 11. Proposed hypothesis for the mechanism of action of DMA. From gene expression analysis, important inducers of NFkB-CREB3L4,
TRERF, ASCC3, HIF1A and MAP3K14 were observed to be activated. Moreover, HSP70 was found to be downregulated which inhibits NFkB activation
at the level of I kappa B Kinase. Suppression of chaperones, folding catalysts, stress responsive genes in DMA treated cells further adds onto cellular
proliferation. Thus, in cells treated with DNA minor groove binding ligand DMA, induction of NFkB inducing kinase and related transcription factors
converges onto the propagation of the pro-survival signal.
doi:10.1371/journal.pone.0039426.g011
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further work in normal cells and animal model experiments can
lead to development of a novel radioprotector with enhanced
survival and radioprotection with less cytotoxicity which is a
major drawback among most other well known radioprotectors.
It was suggested that coactivation of prosurvival ATM/ERK/
NFkB pathway offer an effective therapeutic approach for
enhancing radiation tolerance in human skin cells [50]. Several
groups have tested the effects of NFkB inhibitors on cellular
radiosenstivity and shown that the NFkB activity is necessary for
enhancing cell survival under high dose radiation. In addition, it
was also observed that IKKbdependent NFkB activation
provides radioprotection to the intestinal epithelial cells [51].
Similarly our results suggests that, DMA activates the NIK/
IKKa/IKKb mediated NFkB activation providing protection to
cells from higher c –radiation doses.
Materials and Methods
Cell Culture
The human glioma cell line U87 was obtained from the
National Centre for Cell Science (Pune, India). MCFA10A was
obtained from American Type Culture Collection (ATCC) USA
and HDF cells were obtained from Dermatology department at
Emory University School of Medicine, Atlanta, GA, USA. These
cells lines were maintained according to the ATCC recommen-
dations at 37uC, 5% CO2, in DMEM supplemented with 10%
heat inactivated FCS, 50 units/ml penicillin, 50 mg/ml strepto-
mycin. Cells were cultured, grown until , 80% confluent,
trypsinized and seeded in 90 mm culture dishes for 24 h before
experiments.
We have used U87 cells for the present study due to number of
reasons. Earlier, we have showed in BMG1 cell line (Glioma cells)
that DMA is a noncytotoxic radioprotector. We measured the
radio sensitivity of U87cells with a standard clonogenic assay [52]
and found U87 cells were medium sensitive to radiation and
survival of these cells, after radiation is higher than other cells.
U87 cell lines possess wild type p53 status and have been taken up
as a system for studying irradiation and cytoprotective effects
previously [53–56]. Amifostine, a radioprotector which is in
clinical trial and lot of previous work was done and validated with
U87 cells.
DMA and Exposure Conditions
DMA was synthesized in our laboratory as described
previously [19]. IC50 for DMA was determined at 100 mMi n
U87 cells. Radioprotection survival assay was performed using
increasing dose of DMA from 0–100 mM concentration at four
different radiation doses- 2, 5, 8.5 and 10 Gy respectively (data
not shown). The radiation dose (8.5 Gy) and drug dose (50 mM)
was determined by clonogenecity assay at increasing ligand
concentration as well as increasing radiation dose. From the
clonogenecity assay it was observed that, 50 mM at 8.5 Gy
provided best radioprotection. At higher radiation dose most of
the cells died in DMA untreated cells (control cells). Hence, in
this study all the experiments were performed at 50 mM DMA
with or without 8.5 Gyradiation. Stock of DMA was prepared in
methanol and further dilution to 1 mM was done using DMEM.
This solution was then filtered & sterilized and U87 cells were
subjected to DMA treatment at a final concentration of 50 mM
for 1 h. Four treatment conditions were studied- control
(untreated), ligand treated (50 mM DMA), radiation treated
(8.5 Gy radiation) and ligand + radiation treated (50 mM
DMA+8.5 Gy radiation).
Irradiation Procedure
1 h subsequent to DMA treatment, cells were exposed to 8.5 Gy
c- irradiation (1.3 Gy/min dose rate) using Co-60 source (Institute
of Nuclear Medicine and Allied Sciences, Delhi, India). Following
irradiation, cells were incubated for 4 h in a 5% CO2 humidified
incubator. Trypsin was used to detach the cells. Cells were
centrifuged, washed twice in 1X PBS (pH 7.4) and processed for
further sample preparation.
Metabolic Viability Assay
Exponentially growing U87, HDF and MCF10A cells were
plated at cell densities 3000 cells per well in 96-well tissue culture
plates. After 24, 48 and 72 h cells were treated with increasing
concentrations of DMA i.e.; 0.1–150 mM. Cytotoxicity was
measured by MTT assay according to the manufacturer’s
instructions (Promega, Madison, WI, USA). The experiments
were performed in triplicate and repeated thrice. The percentage
survival was calculated as percent of 570 nm OD of DMA treated
cells to that of DMA untreated control cells with 630 nm OD as
reference.
Percentage survival = (Calculated difference between mea-
surement and reference OD of DMA treated cell/Calculated
difference between measurement and reference OD of DMA
untreated cell) X 100.
Microarray Hybridization and Analysis
Total RNA was extracted from the cell lines using Tri Reagent
(Ambion), digested by DNase (RNase free, MBI Fermentas) and
purified using Qiagen
TM RNeasyminikit. RNA concentration and
purity was determined using NanoDrop spectrophotometer
(Thermo Fischer, MA, USA). RNA quality was evaluated by
Agilent 2100 BioAnalyzer (Agilent Technologies Inc., Palo Alto,
CA), and RNA integrity number (RIN) was found9.0. The 5.0 mg
of total RNA was used for amplification using the Express ArtH
mRNA amplification kit. Amplified aRNA (aminoallyl antisense
RNA) was then labelled with Cy3
TM post-labelling reactive dye
pack (GE Healthcare, United Kingdom) at RT. 20 mg of the
labelled aRNA in 200 ml of Ocimum’sHyb buffer was denatured
at 95uC for 3 min and 100 ml was used for hybridization
performed at 50uC for 2 h on Tecan HS 4800 automated Hyb
station. Human 40 KA and 40 KB OciChip
TM (OcimumBiosolu-
tions, Hyderabad) consisting of 20160 and 19968 spots respectively
were printed on CorningH epoxy coated glass slides using
Omnigrid (Gene Machines). Oligos were printed using spotting
buffer A at 50% humidity and 22uC. The RNA samples were then
hybridized and processed according to OciChip
TM 40K Array
manual specifications. For each treatment condition, three
independent experiments were performed. Hybridized Chips were
scanned using Affymetrix 428
TM array scanner at three different
PMT gains setting- 40, 50, 60. Data were collected and stored as
Tiff images and further analyzed using Imagene software. The
mean background intensity was subtracted from the mean target
intensity to produce the signal intensities. Initial dataset that
consisted of 40,320 probes was filtered to exclude quality control
(QC) probes and empty spots. The data was transformed using
log-transformation and median absolute deviation was performed.
After normalization, genes in the treatment groups with at least
two-fold change in expression were considered as up-regulated or
downregulated in comparison to non treatedcells (control). To
determine significant proportions of differentially expressed genes
within functional groups, the hypergeometric probability P was
calculated. P,0.005 was considered significant. The gene
expression values generated were analyzed using online available
tool- PANTHER (www.pantherdb.org).All microarray data are
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Expression Omnibus (GEO) with accession number GSE30043.
The individual accession number of genes is mentioned in the
table 2.The links for access to microarray data submitted to the
GEO are as mentioned below:
http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE30043(U87 cell line).
Protein Extraction, 2D PAGE and Image Analysis
Protein samples were prepared from cells harvested from DMA
and radiation treated cells as described elsewhere [57]. Cells were
lysed in lysis buffer containing 8 M urea, 0.5% (w/v) CHAPS, 50
mMTris, 0.2% (w/v) Bio-Lyte 4/7, 50 mM DTT, 1 mM PMSF,
1 mM EDTA, 10% (v/v) Glycerol and 1–2 mg/ml protease
inhibitor cocktail (Bio-Rad, Hercules, CA), vortexed at RT for
10 min, incubated on ice for 15 min and centrifuged in a
microcentrifuge at 12,000 rpm for 10 min. The protein concen-
tration was determined using the Bradford method with bovine
serum albumin as a standard. The supernatant was combined with
200 ml of rehydration Buffer (Bio-Rad) containing 8 M urea, 2%
CHAPS, 50 mM DTT, and 0.2% (w/v) Bio-Lyte 4/7 ampholytes,
before isoelectric focusing. First dimensional separation of proteins
(200 mg of protein in 200 ml) was performed on Ready Strip IPG
strips (pH 4/7, 11 cm; Bio-Rad) for a total of 30,000 V-hours.
The second dimensional separation was performed on a 12%
acrylamide gel following DTT reduction and IAA alkylation. The
gels were subsequently stained with Coomassie Brilliant Blue R250
and scanned using a Gel Documentation System (Alpha Imager) at
300 dpi and saved as a gray scale tiff file. Images were analyzed
using Bio-Rad’s PD Quest software. The protein pattern
differences between the control, radiation treated and DMA
treated samples were elucidated by analyzing images from each
sample using Bio-Rad’s PD Quest software. For each treatment
sample, three independent experiments were performed. The
software assigns a standard spot parameter number based on the
quality and type of spots. Using the Gaussian Model during Test,
quality and quantity values were assigned to spots based on total
quantity in valid spots following normalization.
In-Gel Trypsin Digestion and ESI-MS/MS
Differentially regulated protein spots were excised from gels and
destained using 50 mM Ammonium Bicarbonate and 50%
Acetonitrile. Spots were subsequently dried using 100% Acetoni-
trile, speed dried under vacuum and digested with 20 ng/ml
trypsin (Promega Trypsin Gold, Mass Grade) in 25 mM
Ammonium Bicarbonate overnight at 37uC. Peptides were
extracted from gel pieces using 60% Acetonitrile, 0.5% Formic
Acid. Samples were purified using a C18 microbed column
(Millipore ZipTip). Samples were then analyzed by Electro-
SprayIonization tandem mass spectrometry (ESI-MS/MS; Ap-
plied Biosystems Q-Star XL) at a voltage of 1200 V. Sample
spectra were acquired using TOF MS and tandem mass spectral
data as well as using an IDA (information dependent acquisition)
feature in the Analyst QS software. The IDA experiments selected
multiply charged precursors (charged state from 2 to 5) for
fragmentation with an intensity threshold of 10 counts per second.
Precursor ions were excluded for 60 seconds using a window of 6
atomic mass units and collision energy settings were automatically
determined by IDA based on m/z values.
Database Queries and Protein Identifications
The acquired tandem mass spectral data were queried against
protein database using the MASCOT search engine (version 1.8,
Matrix Science Ltd., U.K.) with a mass tolerance of 100 ppm and
one trypsin miscleavage. Carbamidomethylation of cysteine was
set as variable amino acid modifications. For a given sequence, the
EST analyzer searched NCBInr protein database to identify a
homologous protein (the best hit of BLASTX search), then used
the homologous protein to annotate the query sequence. Proteins
with MOWSE scores equal to the accepted significant threshold
(determined at 95% confidence level as calculated by MASCOT)
were reported in this study.
Pathway Construction
Online resources (NCBI, Gene Cards, OMIM and KEGG)
were used to construct a pathway for proteins identified from 2D
PAGE and their interacting partners. This pathway was utilized to
identify the candidate genes.
Real Time RT- PCR
The transcript levels of genes identified from 2D PAGE were
analyzed for their expression by Real-Time Polymerase Chain
Reaction (RT-PCR) using gene specific primers obtained from
Sigma Aldrich (Table 3). RNA was isolated using TriReagent
(Ambion), digested with DNase I (MBI Fermentas) and purified
using Qiagen
TM RNeasy mini kit. RNA samples were quantified
using NanoDrop Spectrophotometer. The RIN was found to be
8.0.1 mg of RNA sample was converted into cDNA, and transcript
levels were quantitated using Sybr Green I (Power Sybr Green I,
Applied Biosystems) and Roche’s light cycler 480 instrument
(LC480) according to manufacturer’s guidelines. b Actin gene was
used as a internal control. Each experiment for samples was
performed three times independently. The calculations and data
analysis were done using the efficiency calibrated mathematical
model for the relative expression ratio in real time PCR [58].
Expression Vectors
The construct for NIK was obtained by cloning the requisite
sequence into p3XFLAG CMV10 generously provided by Dr. P.
C. Rath, School of Life Sciences, Jawaharlal Nehru University,
Delhi. The construct of the NFkB-driven luciferase reporter gene
and corresponding control construct for Renilla luciferase were
kindly provided by Dr. Balram Ghosh, Institute of Genomics and
Integrative Biology, Delhi.
Transfection with Expression Vectors
The day before transfection, 6 well plates were seeded with
2610
5 cells/well in serum containing antibiotic free medium. The
cells were incubated at 37uC in a 5% CO2 incubator overnight.
For each well, plasmid was prepared in required volume of serum
free medium. Transfectin
TM Lipid Reagent (Bio-Rad, Hercules,
CA) was prepared in serum-free medium. The DNA and
Transfectin solutions were mixed together and incubated for
20 min at room temperature. DNA-Transfectin complexes were
added directly to cells in serum-containing medium and swirled
gently. Cells were incubated at 37uC in a 5% CO2 incubator.
Additional media was added 4–6 h after addition of complexes.
After 48 h, cells were harvested and assayed for protein
expression.
Cloning and Expression of NFkB Inducing Kinase
RNA was extracted from HEK cell line and cDNA was
synthesized. The cDNA template of NFkB inducing kinase was
amplifiedbyPCRwithsenseprimerNIKFP(59-TCTAGAATGG-
CAGTGATGGAAATG-39) and antisense primer NIK RP (59-
GGATCCTTAGGGCCTGTTCTCC-39) using Phusion DNA
polymerase (Finnzymes, Finland) and cloned into p3XFLAG
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purifiedusingEndoFreePlasmidMaxiKit(QIAGEN
TM)according
to manufacturer’s guidelines and dissolved in TE buffer (pH 7 to 8),
before using for transfection. The transient transfection of the
constructed plasmid was done by Transfectin Lipid Reagent (Bio-
rad) according to the manufacturer’s guidelines.
Knockdown of NIK using siRNA
In a 6 well tissue culture plate, human glioma (U87) cells were
plated (2610
5 cells/well) in antibiotic free media supplemented
with FBS. After 24 h, cells were transfected with siRNA-NIK (sc-
36065, Santa Cruz Biotechnology Inc.) and control-siRNA (sc-
37007, Santa Cruz Biotechnology Inc.) according to the manu-
facturer’s instructions. Knockdown of NIK was observed at 50 pM
concentration of siRNA-NIK (Figure S1).
Immunoblot Analysis
Human glioma (U87) cells were transfected with p3XFLAG
CMV10- NIK, siRNA-NIK and control-siRNA using Transfectin
(Lipid Reagent) according to manufacturer’s guidelines. For the
experiment following transfections, cells were treated with 50 mM
DMAfor1 h.Subsequently,cellswereinducedwithTNF-a(10 ng/
ml) for 0,5,10,20,40,60 min and irradiated at 8.5 Gy.Trypsin was
used to detach the cells and the cells were collected, centrifuged at
2000 rpm for 2 min and resuspended in RIPA buffer (50mM Tris-
HCl, pH 7.6, 150 mM NaCl, 1% sodium deoxycholate, 10%
sodium orthovanadate and cocktail of protease inhibitors) on ice for
30 min. Following centrifugation at 25,000 g for 30 min, the
supernatant was collected as total cell lysate and protein concentra-
tionwasdeterminedusingBradford’sAssay.Sampleswereprepared
in SDS gel loading buffer (625 mM Tris pH 6.8, 10% SDS, 25%
glycerol, 100 mM DTT and 0.015% bromophenol blue). Western
blotting was performed using standard protocols with antibodies
against human IKKa, IKKb,I kBa, phospho-IKKa/IKKb (180/
181) (Santa Cruz Biotechnology Inc.) and horseradish peroxidase-
conjugated mouse anti-human immunoglobulin (secondary anti-
body, Abcam). Detection was done by an enhanced chemilumines-
cence (ECL) system (Pierce).
Proliferation Kinetics
U87 Cells post siRNA oligonucleotide transfections were treated
with 50 mM DMA and 8.5 Gyradiation. Post treatment cells were
seeded in 6 well plates at 8000 cells per well, and their proliferation
kinetics was studied at 24 h intervals following trypsinization and
counting total cells per well using a hemocytometer. Same
experiment was done with control siRNA-transfected U87 cells.
Percentage (%) radioprotection of cells was calculated by following
formula.
% growth of Radiation treated cells = (Number of cells in
Radiation treated cells/Number of cells in only DMA treated cells)
X 100.
% growth of DMA+Radiation treated cells = (Number of cells
in DMA+ Radiation treated cells/Number of cells in only DMA
treated cells) X 100.
% Radioprotection = % growth of DMA+Radiation treated
cells - % growth of Radiation treated cells.
Cell-cycle Analysis
U87 cells (2610
5 cells/plate) in 60 mm plates, transfected with
control siRNA and siRNA-NIK, were cultured and DMA,
Radiation and DMA + Radiation treatment were given as
described earlier. After irradiation, cells were collected after the
incubation period of 0,3,6,12,18 and 24 h. After incubation cells
were collected, washed twice with ice-cold PBS, and fixed in 70%
ethanol. Cell pellets were stored at 4
oC for 24 h. Cells pellets were
washed twice with ice-cold PBS and stained with 0.5 mL of RNase
(2 mg/mL) and 0.5 mL of propidium iodide (0.1% in 0.6% Triton
X-100 in PBS) for 30 minutes in dark. Samples were then analysed
on a FACSCalibur flow-cytometer (Becton Dickinson).
Annexin-V Staining
U87 cells (2610
5 cells/plate) in 60 mm plates, transfected with
control siRNA and siRNA-NIK, were cultured and DMA,
Radiation and DMA +Radiation treatment were given as
described earlier. After irradiation, cells were incubated for 3, 6,
12, 18 and 24 h (data not shown for 12 and 18h). Cells were
collected by mild trypsinization and were pooled together with
detached cells of respective group. Samples were prepared
according to the manufacturer’s instructions (BD Pharmingen
TM
Annexin V: FITC Apoptosis Detection Kit I, Catalog Number
556547, USA) and the samples were subjected to flow cytometry
analysis (Becton Dickinson).
Luciferase Reporter Assay for NFkB Activity
The effect of DMA on TNF-a induced NFkB dependent
reporter gene transcription was measured. Briefly, human glioma
(U87) cells (2610
4 cells/well) were plated in 96 well plates. Next
day cells were following serum starvation, cells were co-transfected
Table 3. Sequences of primers used for quantitation of gene expression.
S. No. Gene Primer sequences (FP- forward primer; RP-reverse primer) Tm (6C)
1. MAP3K3 FP-GAACTCCCCCTCACTGTTGA
RP-GAAGCAGGCACCTCTCTGTC
60.0
60.1
2. MAP3K7 FP-CAAACAACTCCAAAGGCTCC
RP-CTCCTCCTCCTCCTCGTCTT
59.7
59.9
3. MAP3K14 FP-CCCTTCTCTCACAGCTCCAT
RP-ATGGAGGACAAGCAGACTGG
59.4
60.2
4. MAPK10 FP-TTCACATCCAATGTTGGTTCA
RP-CAGGCCCATCTCAGATCTTC
59.8
59.7
5. YWHAZ FP-GAAGCATTGGGGATCAAGAA
RP-ACAAAAGACGGAAGGTGCTG
60.0
60.2
6. NFkB FP-CCACCTTTACGAGGACCTATTCC
RP- CAGCACTCGCTCTCCATGAA
60.1
60.3
doi:10.1371/journal.pone.0039426.t003
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Transfectin
TM Lipid Reagent (Bio-Rad, Hercules, CA) and b-
galactosidase reporter vector (used as an internal control)
according to the manufacturer’s instructions. pNFkB-Luc contains
the firefly luciferase (luc) gene from Photinuspyralis. This vector also
contains multiple copies of the NFkB consensus sequence fused to
a TATA-like promoter (PTAL) region from the Herpes Simplex
Virus thymidine kinase (HSV-TK) promoter. After endogenous
NFkB proteins bind to the kappa (k) enhancer element
(GGGAATTTCCGGGAATTTCCGGGAATTTCCGG-
GAATTTCCGGGAATTTCCGGGAATTTCC), transcription
is induced and the reporter gene is activated. Twenty four hours
after transfection, U87 cells were treated with DMA
(0,10,25,50 mM) for 1 h prior to irradiation at 8.5 Gy. Following
irradiation, induction with TNF-a (20 ng/ml) was done for 4 h to
induce NFkB driven luciferase expression. Subsequently, cells
were assayed for reporter activity using Dual
TM Luciferase
Reporter Assay System (Promega) according to the manufacturer’s
guidelines.The relative luciferase activity was calculated by
normalizing results with the b –galactosidase expression.
Statistical Analysis
Data are expressed as means 6SD. Statistical significance
among groups was determined using the Student t test and the
differences were considered significant at P,0.05.
Supporting Information
Figure S1 Knock down of NFkB inducing kinase gene
expression using siRNA against NFkB inducing kinase.
(A) Lanes 1-5 - RT-PCR with siRNA treated cells with NFkB
inducing kinase primers (control, 20 pM siRNA-NIK,50 pM
siRNA-NIK,80 pM siRNA-NIK, NTC); Lanes 6-10- RT-PCR
with siRNA treated cells with ACTB primers (control, 20 pM
siRNA-NIK,50 pM siRNA-NIK,80 pM siRNA-NIK, NTC); M
(DNA ladder). (B) Lanes 1-5 - RT-PCR with control siRNA
treated cells with NFkB inducing kinase primers (control, 20 pM
siRNA-NIK,50 pM siRNA-NIK,80 pM siRNA-NIK, NTC)
Lanes 6-10- RT-PCR with siRNA treated cells with ACTB
primers (control, 20 pM siRNA-NIK,50 pM siRNA-NIK,80 pM
siRNA-NIK, NTC); M (DNA ladder).
(TIF)
Table S1 Differentially regulated proteins identified by
2D PAGE and ESI-MS/MS analysis.
(DOCX)
Table S2 MS/MS analysis of reported proteins.
(DOCX)
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